Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 16, 2025

Online Casino Bonuses: BitStarz Outlines 2025 New Welcome Bonuses for Real Money Players

View original at globenewswire.com
Online Casino Bonuses: BitStarz Outlines 2025 New Welcome Bonuses for Real Money Players New York City, , Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dec 16, 2025, BitStarz, a well-known online casino, has become a popular choice for players exploring online casino bonuses…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BitStarz stands out for its structured bonus system and transparent terms, making it easier for players to understand and use their rewards effectively

    80% confidence

  • BitStarz was one of the first online casinos to accept other currencies, giving it an advantage over many older casinos that only used regular money

    80% confidence

  • The real value of any online casino's best bonus depends less on headline numbers and more on conditions such as wagering requirements and withdrawal limits

    80% confidence

  • Search interest for real money online casino no deposit bonus codes remains high, yet such offers have become increasingly rare due to regulatory pressure and abuse risks

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Online Casino Bonuses: BitStarz Outlines 2025 New Welcome Bonuses for Real Money Players — Source | Via News | Via News